Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion. As we ...

Some 17,000 Brits are battling with sickle cell disease but despite the risk of life-threatening complications, sickle cell ...

in patients aged 12 years and older who have sickle cell disease. However, just weeks ago Pfizer pulled the drug in a voluntary market withdrawal over its potential impacts on those taking it ...

The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...

Researchers described a promising new approach for using gene therapy to treat sickle cell disease in the journal Human Gene ...

This transformative gift from Ted W. Love, M.D., and Joyce Y. Love will improve patient care for those with sickle cell ...

The EU's drug watchdog Thursday called for the suspension of approval for Pfizer's medicine to treat sickle cell disease, saying doctors should stop using the drug. The incidence of stroke ...

To pave the way for the launch of Oxbryta, Pfizer’s GBT unit approached Riester Rx to conduct research and develop a market-shaping campaign to increase awareness of sickle cell disease.